Research Analysts Set Expectations for DWTX FY2024 Earnings

Dogwood Therapeutics, Inc. (NASDAQ:DWTX) – Zacks Small Cap issued their FY2024 earnings per share (EPS) estimates for Dogwood Therapeutics in a note issued to investors on Tuesday, March 18th. Zacks Small Cap analyst D. Bautz forecasts that the company will post earnings per share of ($6.43) for the year. The consensus estimate for Dogwood Therapeutics’ current full-year earnings is ($6.43) per share. Zacks Small Cap also issued estimates for Dogwood Therapeutics’ Q4 2024 earnings at ($1.49) EPS, FY2025 earnings at ($4.57) EPS and FY2026 earnings at ($1.90) EPS.

Dogwood Therapeutics Stock Performance

Shares of DWTX stock opened at $6.33 on Friday. Dogwood Therapeutics has a 12 month low of $1.62 and a 12 month high of $29.28. The company’s 50 day moving average is $7.28. The firm has a market capitalization of $8.43 million, a P/E ratio of -0.97 and a beta of 2.07.

Hedge Funds Weigh In On Dogwood Therapeutics

A hedge fund recently bought a new stake in Dogwood Therapeutics stock. Geode Capital Management LLC acquired a new position in Dogwood Therapeutics, Inc. (NASDAQ:DWTX) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 10,933 shares of the company’s stock, valued at approximately $27,000. Geode Capital Management LLC owned about 0.82% of Dogwood Therapeutics at the end of the most recent quarter. Institutional investors and hedge funds own 9.05% of the company’s stock.

Dogwood Therapeutics Company Profile

Dogwood Therapeutics, Inc is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia.